Advertisement

Topics

Roche presents new data from GALLIUM study reinforcing clinical benefit of Gazyva/Gazyvaro in people with previously untreated follicular lymphoma

02:30 EDT 23 Jun 2017 | Hoffmann-La Roche Ltd

Roche announced today that new data from additional analyses of the pivotal phase III GALLIUM study in people with previously untreated follicular lymphoma will be presented at the 22nd European Hematology Association (EHA) annual congress, 22-25 June, in Madrid, Spain.

Original Article: Roche presents new data from GALLIUM study reinforcing clinical benefit of Gazyva/Gazyvaro in people with previously untreated follicular lymphoma

NEXT ARTICLE

More From BioPortfolio on "Roche presents new data from GALLIUM study reinforcing clinical benefit of Gazyva/Gazyvaro in people with previously untreated follicular lymphoma"

Advertisement
Quick Search
Advertisement
Advertisement